Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278–4286].
Saved in:
| Title: | Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278–4286]. |
|---|---|
| Authors: | Maréchal, Céline1 celine.x.marechal@gsk.com, Lal, Himal1, Poder, Airi1, Ferguson, Murdo1, Enweonye, Igwebuike1, Heineman, Thomas C.1, Hervé, Caroline1, Rheault, Paul1, Talli, Jaak1, Wauters, Dominique1, Oostvogels, Lidia1 |
| Source: | Vaccine. Feb2019, Vol. 37 Issue 9, p1252-1253. 2p. |
| Database: | Environment Complete |
Be the first to leave a comment!
